Is the price fair?
What NVAX's price assumes
Novavax, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 2.23× revenue.
2.23
Price / sales · no P/E: the last twelve months did not end in a profit
- EV / sales
- 2.33
EV / sales
Details›
- EV / EBIToperating margin −13%: the multiple describes the denominator
- not meaningful
- EV / sales2026-Q1
- 2.33
- Market capitalisation
- $1.41B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.